Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Dexmedetomidine, a central and peripheral α2-receptor agonist distinct from GABA receptor for benzodiazepines and propofol, has been approved by the US Food and Drug Administration only for use up to 24 h in mechanically ventilated patients. The investigators aim to compare dexmedetomidine with propofol for sedation >24h in poly traumatized mechanically ventilated patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Dexmedetomidine; Propofol

Criteria

Inclusion Criteria:

• Endotracheal Intubation

• Mechanical ventilation

• Poly traumatized

• ICU patients and estimated duration of sedation>24 h.

Exclusion Criteria:

• Patients with serious trauma in the central nervous system,

• with bleeding probably requiring surgical hemostasis,

• drug overdose within the last 30 days before study entry,

• pregnancy/lactation,

• contraindication to alpha-2-adrenoceptor agonists or antagonists,

• cardiovascular disease,

• conduction disturbances or difficulty in data collection or completing the study protocol